|

A Long-term Follow-up Study of Patients With ARD103 CAR-T Cell Therapies

RECRUITINGSponsored by ARCE Therapeutics, Inc.
Actively Recruiting
SponsorARCE Therapeutics, Inc.
Started2026-05-12
Est. completion2040-05-30
Eligibility
Healthy vol.Accepted
Locations3 sites

Summary

This study will evaluate the long-term safety of ARD103 cellular therapies

Eligibility

Healthy volunteers accepted
Inclusion Criteria:

* The participant has R/R AML or MDS and has previously received ARD103 CAR-T cell therapies in the parent study.
* The participant is able to understand and comply with protocol-required study procedures and has provided a written informed consent document.

Exclusion Criteria:

* There are no specific exclusion criteria for this study

Conditions4

Acute Myeloid Leukemia, in RelapseAcute Myeloid Leukemia, in Relapsed or RefractoryCancerMDS (Myelodysplastic Syndrome)

Locations3 sites

North Carolina

2 sites
Novant Health Cancer Institute
Kunal Shah980-302-6297kashah@novanthealth.org
Novant Health Cancer Institute
Winston-Salem, North Carolina, 27201
Gait Jordan336-718-8553PJordan@novanthealth.org

Texas

1 site
MD Anderson Cancer Center
Houston, Texas, 77030
Dr. Abhishek Maiti713-745-3228AMaiti@mdanderson.org

Find trials near these locations

Browse More Trials

Trial data from ClinicalTrials.gov. Trial status and eligibility can change — verify directly with the study contact or on ClinicalTrials.gov.

This site does not provide medical advice. Always consult your doctor before considering enrollment in a clinical trial. Learn more on our About page.